移植物抗宿主疾病 (GVHD) 市場 - 按疾病類型、治療類型、年齡層、給藥途徑、配銷通路- 全球預測 2024 - 2032 年

由於擴大採用造血幹細胞移植（HSCT）程序，特別是在血液惡性腫瘤和自體免疫疾病的治療方面，移植物抗宿主疾病（GVHD）市場規模預計在2024年至2032年期間年複合成長率為8.1%。根據美國國立衛生研究院的數據，每年約進行 5 萬例幹細胞移植，年增率在 10% 至 15% 之間。由於HSCT仍然是多種疾病的重要治療方式，GVHD的發生率預計將相應上升。醫療技術和移植手術的快速進步提高了移植受者的存活率。

醫療保健提供者和患者意識的提高進一步凸顯了早期檢測和及時干預在 GVHD 管理中的重要性。及時診斷可以啟動適當的治療策略，從而降低 GVHD 的嚴重程度並改善患者的預後。正在進行的研發活動專注於開發具有改善功效和安全性的新型療法，這將進一步推動市場擴張。

GVHD產業分為疾病類型、治療類型、年齡層、給藥途徑、配銷通路和地區。

根據治療類型，由於皮質類固醇具有強大的抗發炎和免疫抑制特性，預計到 2032 年，其市場規模將以 7.8% 的速度成長。皮質類固醇有多種劑型，包括口服、靜脈注射和外用製劑，可提供給藥靈活性，並可根據 GVHD 表現的嚴重程度和部位制定量身定做的治療方法。

就給藥途徑而言，移植物抗宿主疾病市場的口服部分預計在 2024 年至 2032 年期間複合年成長率為 8.4%。口服藥物為患者提供方便和易於給藥，確保臨床環境之外的自我管理並促進對治療方案的依從性。這種可近性提高了患者的依從性，同時改善了治療結果和整體生活品質。

亞太地區移植物抗宿主疾病產業在 2024 年至 2032 年期間將以 8.5% 的複合年成長率實現令人矚目的成長。這可以歸因於造血幹細胞移植（HSCT）手術發生率的上升，特別是在醫療基礎設施不斷發展和移植服務獲得改善的國家。當地醫療機構、製藥公司和研究組織之間不斷加強的合作正在促進針對臨床需求的新型 GVHD 療法的開發，進一步刺激區域市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 血液疾病盛行率增加
    • 移植技術的進步
    • 研發投資不斷增加
    • 不斷成長的治療藥物管線
  • 產業陷阱與挑戰
    • 治療費用高
    • 嚴格的監管挑戰
    • 併發症和復發的風險
• 成長潛力分析
• 管道分析
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀錶板

第 5 章：市場估計與預測：按疾病類型，2021 - 2032

• 主要趨勢
• 急性移植物抗宿主疾病（aGVDH）
• 慢性移植物抗宿主疾病（cGVDH）

第 6 章：市場估計與預測：按治療類型，2021 - 2032 年

• 主要趨勢
• 單株抗體
• mTOR抑制劑
• 酪胺酸激酶抑制劑
• 免疫抑制劑
• 皮質類固醇
• 其他治療類型

第 7 章：市場估計與預測：按年齡分類，2021 - 2032

• 主要趨勢
• < 20 年
• 21-50歲
• 51歲以上

第 8 章：市場估計與預測：按管理途徑，2021 - 2032 年

• 主要趨勢
• 口服
• 靜脈
• 專題

第 9 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 10 章：市場估計與預測：按地區，2021 - 2032

• 主要動向：按地區
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 中東和非洲其他地區

第 11 章：公司簡介

• Astellas Pharma Inc.
• Bristol Myers Squibb
• ElsaLys Biotech SA
• Incyte Corporation
• Johnson & Johnson Services, Inc.
• Kiadis Pharma
• Mallinckrodt Pharmaceuticals
• Merck & Co., Inc.
• Mesoblast Ltd
• Neovii Pharmaceuticals AG
• Novartis AG
• Pfizer Inc.
• Sanofi
• Soligenix

Graft versus host disease (GVHD) market size is estimated to register 8.1% CAGR between 2024 to 2032, driven by the increasing adoption of hematopoietic stem cell transplantation (HSCT) procedures, particularly in the treatment of hematologic malignancies and autoimmune disorders. As per National Institute of Health, approximately 50,000 stem cell transplants are conducted annually, experiencing an annual growth rate ranging between 10% to 15%. As HSCT remains a crucial treatment modality for various diseases, the incidence of GVHD is expected to rise correspondingly. Rapid advancements in medical technology and transplant procedures have led to improved survival rates among transplant recipients.

Increased awareness among healthcare providers and patients is further outlining the importance of early detection and prompt intervention in GVHD management. Timely diagnosis allows the initiation of appropriate treatment strategies, thereby reducing the severity of GVHD and improving patient outcomes. The ongoing R&D activities focused on the development of novel therapeutics with improved efficacy and safety profiles will further propel the market expansion.

The GVHD industry is segmented into disease type, treatment type, age group, route of administration, distribution channel and region.

Based on treatment type, the market size from the corticosteroids segment is anticipated to witness 7.8% growth rate through 2032, due to their potent anti-inflammatory and immunosuppressive properties. Corticosteroids are widely available in various formulations, including oral, intravenous, and topical preparations for offering flexibility in administration and enabling tailored treatment approaches based on the severity and site of GVHD manifestations.

With regards to route of administration, the oral segment in the graft versus host diseases market is anticipated to observe 8.4% CAGR during 2024-2032. Oral medications offer patients convenience and ease of administration ensuring self-management outside of clinical settings and promoting adherence to treatment regimens. This accessibility is enhancing patient compliance while leading to improved treatment outcomes and overall quality of life.

Asia Pacific graft versus host disease industry will record impressive growth at 8.5% CAGR over 2024-2032. This can be attributed to the rising incidence of hematopoietic stem cell transplantation (HSCT) procedures, particularly in countries with growing healthcare infrastructure and improved access to transplant services. Rising collaborations between local healthcare institutions, pharmaceutical companies, and research organizations is fostering the development of novel GVHD therapies tailored to the clinical needs, further stimulating the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of hematological disorders
    • 3.2.1.2 Advancements in transplantation techniques
    • 3.2.1.3 Rising investments in research and development
    • 3.2.1.4 Growing pipeline of therapeutic agents
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High treatment cost
    • 3.2.2.2 Stringent regulatory challenges
    • 3.2.2.3 Risk of complications and relapse
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Acute graft versus host disease (aGVDH)
• 5.3 Chronic graft versus host disease (cGVDH)

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Monoclonal antibodies
• 6.3 mTOR inhibitors
• 6.4 Tyrosine kinase inhibitors
• 6.5 Immunosuppressants
• 6.6 Corticosteroids
• 6.7 Other treatment types

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 < 20 years
• 7.3 21-50 years
• 7.4 51 years and above

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Intravenous
• 8.4 Topical

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

• 10.1 Key trends, by region
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Astellas Pharma Inc.
• 11.2 Bristol Myers Squibb
• 11.3 ElsaLys Biotech SA
• 11.4 Incyte Corporation
• 11.5 Johnson & Johnson Services, Inc.
• 11.6 Kiadis Pharma
• 11.7 Mallinckrodt Pharmaceuticals
• 11.8 Merck & Co., Inc.
• 11.9 Mesoblast Ltd
• 11.10 Neovii Pharmaceuticals AG
• 11.11 Novartis AG
• 11.12 Pfizer Inc.
• 11.13 Sanofi
• 11.14 Soligenix